Cellectis Issues Earnings Results
CLLS Stock | USD 2.13 0.01 0.47% |
Slightly above 62% of Cellectis' investor base is looking to short. The analysis of the overall investor sentiment regarding Cellectis SA suggests that many traders are alarmed. Cellectis' investing sentiment can be driven by a variety of factors including economic data, Cellectis' earnings reports, geopolitical events, and overall market trends.
Cellectis |
Cellectis issued its quarterly earnings data on Monday. The biotechnology company reported earnings per share for the quarter, missing the consensus estimate of by , Zacks reports. Cellectis had a negative return on equity of 78.90 percent and a negative net margin of 401.83. The company had revenue of
Read at thelincolnianonline.com
Cellectis Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cellectis can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cellectis Fundamental Analysis
We analyze Cellectis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Cellectis is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cellectis SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectis stock to make a market-neutral strategy. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics with similar companies.
Peers
Cellectis Related Equities
PASG | Passage Bio | 11.94 | ||||
GLUE | Monte Rosa | 5.93 | ||||
RGNX | Regenxbio | 4.82 | ||||
FHTX | Foghorn Therapeutics | 3.59 | ||||
IPHA | Innate Pharma | 3.45 | ||||
DMAC | DiaMedica Therapeutics | 2.56 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
KYMR | Kymera Therapeutics | 1.91 | ||||
CRNX | Crinetics Pharmaceuticals | 1.59 | ||||
GNFT | Genfit | 0.95 | ||||
STTK | Shattuck Labs | 0.93 | ||||
KZR | Kezar Life | 0.40 | ||||
INBX | Inhibrx | 1.15 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
NRIX | Nurix Therapeutics | 2.57 | ||||
SLNO | Soleno Therapeutics | 4.29 | ||||
HCWB | HCW Biologics | 10.71 |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.